Abstract:Immunocompromised individuals are at risk for developing lymphocryptovirus-associated lymphoproliferative diseases, such as Epstein Barr virus (EBV)-associated B cell lymphomas and post-transplant lymphoproliferative disorder (PTLD). We previously reported development of cynomolgus lymphocryptovirus (CyLCV)-associated PTLD in Mauritian cynomolgus macaques (MCMs) undergoing hematopoietic stem cell transplantation (HSCT), which mirrored EBV-PTLD in transplant patients. Here, we sought to develop a MCM model of lymphocryptovirus-associated lymphoproliferative disease in immunosuppressed MCMs without HSCT. Five simian immunodeficiency virus (SIV)-infected, CD8α+ cell-depleted MCMs received an infusion of autologous B-lymphoblastoid cells transformed with CyLCV, followed by varying degrees of immunosuppression. Four of five infused macaques developed masses coincident with increasing CyLCV plasma viremia, and necropsies confirmed the presence of multicentric lymphomas, which most commonly manifested in lymph nodes, gastrointestinal tract, adrenal glands, and pancreas. Affected tissues harbored neoplastic lymphocytes double-positive for CD20 and CyLCV EBNA2 antigen, large frequencies of proliferating B cells, and high levels of cell-associated CyLCV DNA. In addition, longitudinal 18F-fluorodeoxyglucose positron-emission tomography (18F-FDG PET) of one MCM successfully detected lymphoproliferative disease in the adrenal glands prior to clinical signs of disease. These data demonstrate successful induction of lymphocryptovirus-associated PTLD-like disease in 4 of 5 MCMs, and thus support the use of MCMs as a preclinical NHP model of EBV-associated lymphoproliferative disease that could be employed to test novel diagnostic and therapeutic modalities. Post-transplant lymphoproliferative disorder (PTLD) is a significant transplant-related complication that typically results from uncontrolled proliferation of lymphocryptovirus-infected B cells in the absence of sufficient immune surveillance. We sought to develop a nonhuman primate model of PTLD-like disease by infusing lymphocryptovirus-infected B cells into immunosuppressed Mauritian cynomolgus macaques. This strategy successfully induced lymphocryptovirus-associated lymphoproliferative disease in 4 of 5 studied macaques, who developed LCV+ B cell lymphomas. While further studies are needed to determine the optimal immunosuppressive regimen to universally trigger disease, our findings lay the foundation for a physiologically relevant macaque model of lymphocryptovirus-associated PTLD that can be employed to test new therapies.

Campath-1H Depletes Lymphocytes in Blood and Lymphatic Tissues of Cynomolgus Monkeys

Alemtuzumab Used for Induction Therapy in Cynomolgus Model

Lymphocyte depletion and repopulation in peripheral blood and small intestine of cynomolgus monkeys after alemtuzumab treatment.

Lipidomic Perturbations in Cynomolgus Monkeys Are Regulated by Thyroid Stimulating Hormone

CD4+ T cell depletion does not affect the level of viremia in chronically SHIVSF162P3N-infected Chinese cynomolgus monkeys

A Reduction in B, T, and Natural Killer Cells Expressing CD38 by TAK-079 Inhibits the Induction and Progression of Collagen-Induced Arthritis in Cynomolgus Monkeys

Chronic Toxicity Test in Cynomolgus Monkeys For 98 Days with Repeated Intravenous Infusion of Cynomolgus Umbilical Cord Mesenchymal Stem Cells

Translate Pharmacokinetics of PD-1/PD-L1 Monoclonal Antibodies from Cynomolgus Monkey to Human: Comparison of Different Approaches

Effect of Monocyte/macrophages Activated by CpG -Oligodeoxynucleotides of Bacteria on K562 Cells

Use of the ImmuKnow assay to evaluate the effect of alemtuzumab-depleting induction therapy on cell-mediated immune function after renal transplantation

Application of an intermediate concentration of cyclophosphamide does not specifically deplete regulatory T cells in a mouse experimental model

A model of lymphocryptovirus-associated post-transplant lymphoproliferative disorder in immunosuppressed Mauritian cynomolgus macaques

Preclinical Pharmacokinetics and Pharmacology Study of RC98: A Programmed Cell Death Ligand 1 Monoclonal Antibody in Cynomolgus Monkeys

The Effects of Rhil-11 on Hematopoietic Restoration Following Cyclophosphamide-Induced Thrombocytopenia in Cynomolgus Monkeys

Immunomodulatory Properties of Mesenchymal Stem Cells Combined with Mycophenolate Mofetil Induce T Cell Regulation and Prolong Renal Allografts Survival in Cynomolgus Monkeys

Cytological Bone Marrow Cell Differential Counts and Morphologic Findings in Healthy Cynomolgus Monkeys ( Macaca fascicularis) from Nonclinical Toxicology Studies

Systemic toxicity of non-cell corynebacterium parvum (CP) in monkeys.

Species-Specific Involvement of Integrin αIIbβ3 in a Monoclonal Antibody CH12 Triggers Off-Target Thrombocytopenia in Cynomolgus Monkeys.

Effect of bone marrow T lymphocytes treated with CAMPATH 1G on megakaryocyte colony formation

Application of blood microsampling in cynomolgus monkey and demonstration of equivalent monoclonal antibody PK parameters compared to conventional sampling

Depleting Anti-Cd4 Monoclonal Antibody (GK1.5) Treatment: Influence on Regulatory CD4+CD25+Foxp3+ T Cells in Mice.